Why BGPT?
logo

Review Papers Claim by Claim

Check each claim against its experiments, reported results, scope, and stated limitations.Know what the science actually supports before you trust the answer.

Press Enter ↡ to start review



    Explore by Goal












     Quick Explanation


    Core finding (paper): miR-34a is frequently transcriptionally silenced in cancers via aberrant CpG island methylation of its promoter, and restoring miR-34a can drive senescence / cell-cycle arrest (at least partly via CDK6 targeting) in representative cancer cell lines.



     Long Explanation


    Paper Review
    Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer
    DOI: 10.4161/cc.7.16.6533 Β· Publication: Dec 3, 2014 (Cell Cycle issue)
    Claim mapping
    • Mechanism: miR-34a promoter CpG methylation silences pri-/mature miR-34a
    • Prevalence: frequent in primary prostate cancers and present across multiple tumor types (cell lines + some primaries)
    • Function: restoring miR-34a induces senescence / cell-cycle arrest and implicates CDK6 targeting
    1) Visualize reported methylation prevalence
    The paper reports MSP-detected miR-34a promoter CpG methylation frequencies across cancer types (mostly cancer cell lines; plus primary prostate and primary melanoma).
    Skeptical note: These are not population-wide estimates; they reflect specific sample sets (cell lines + selected primary tissues) and the paper uses MSP panels whose sensitivity is assay-specific.
    2) Mechanistic logic chain (from DNA methylation to phenotype)
    1. Background: miR-34a is a p53-associated tumor-suppressive microRNA; prior work established p53 transactivation/functional effects.
    2. Epigenetic mechanism: In cancer models with low pri-/mature miR-34a, the miR-34a promoter CpG island shows dense methylation; the paper uses bisulfite sequencing and shows reduction of methylation after 5Aza-2’dC and reactivation with TSA.
    3. Causality support: Pharmacologic reversion (DNA methyltransferase inhibition + histone deacetylase inhibition) increases pri-miR-34a; the authors interpret this as CpG methylation being causative for downregulation in the relevant lines.
    4. Functional consequence: Restoring pri-miR-34a in selected prostate/pancreas models induces senescence and cell-cycle arrest features, and reduces CDK6 protein; a CDK6 3’UTR reporter indicates responsiveness at binding site BS2.
    Concept graph (paper-only evidence)
    Uncertainty spotlight: The paper explicitly notes cases where miR-34a loss did not align with detectable promoter methylation (i.e., alternative inactivation mechanisms likely exist).
    3) Primary tumor validation vs cell line generality
    • Prostate: The paper reports methylation in 19/24 primary prostate carcinoma cases (79.1%). In situ hybridization (ISH) shows that methylation-positive primary tumors generally lack processed miR-34a signal in most cases (18/19; 94.5%), with limited heterogeneous areas.
    • Melanoma: The paper reports methylation in 19/44 melanoma cell lines and 20/32 primary melanomas, with non-methylated expression in primary melanocytes used as normal controls.
    What would falsify this? If larger, independent cohorts fail to show methylation-expression concordance, or if methylation does not predict loss of processed miR-34a by ISH. The paper’s own observations of discordant cases already imply the mechanism is not universal for every tumor cell.
    4) Evidence triangulation with later literature (still cautious)
    Related evidence (external to this paper)
    • Epigenetic/multimechanism framing: A later review describes multiple regulation layers (p53-dependent and -independent) for the miR-34 axis in cancer. This matters because the original paper claims CpG methylation silences miR-34a and that silencing can be dominant over p53 transactivation in their modelsβ€”later literature suggests additional layers beyond promoter methylation.
    • Biomarker directionality (example): A colon-cancer study reports that miR-34a promoter methylation with elevated c-Met/Ξ²-catenin predicts distant metastasis risk. This is consistent with methylation being informative, but it does not by itself validate promoter methylation causality across cancers.
    Important skepticism: Biomarker associations (diagnostic/prognostic correlations) can reflect passenger epigenetic drift or co-occur with other oncogenic states rather than being mechanistically causal. The original paper does provide mechanistic functional rescue in selected cell lines, but it does not quantify causal effect sizes across diverse in vivo tumor contexts.
    5) Critical appraisal (quality, robustness, and blind spots)
    What the paper does well
    • Triangulation across assay types: expression assessment (RT-PCR/Northern/ISH) is aligned with promoter methylation assessment (bisulfite sequencing/MSP), and pharmacologic epigenetic reversal supports causality in specific lines.
    • Mechanism link to a target: CDK6 reduction and a targeted reporter site (BS2) provide a concrete molecular bridge between miR-34a restoration and cell-cycle arrest phenotype.
    Where robustness may be limited (skeptical)
    • Cell line over-representation: the multi-cancer prevalence panel is dominated by cell lines, which can differ from primary tumor chromatin states. While primary prostate and primary melanoma are included, broad generality claims remain constrained by sample selection.
    • Discordant cases imply additional mechanisms: the paper itself notes methylation-negative expression loss in some contexts, meaning CpG methylation is not the sole inactivation route.
    • Epigenetic drug confounding: 5Aza-2’dC and TSA can affect multiple loci and pathways; the paper interprets rescue as evidence for CpG methylation causality at miR-34a, but off-target chromatin effects are a general concern.
    • Clinical linkage not fully quantified: although the study suggests diagnostic marker potential, the provided text does not show extensive patient outcome modeling (e.g., survival) for this specific paper’s cohort.
    Bottom-line interpretation (with confidence)
    Known from this paper (directly supported by its described data)
    • miR-34a promoter CpG methylation correlates strongly with reduced miR-34a expression in many tested cancer settings, with particularly high concordance in primary prostate carcinomas.
    • Restoring miR-34a in selected prostate/pancreas cancer lines induces senescence/cell-cycle arrest and reduces CDK6 protein; BS2 in CDK6 3’UTR is responsive in a reporter assay.
    What remains uncertain (what would change the conclusion)
    • How universally promoter CpG methylation explains miR-34a silencing across additional tumor types and clinical contexts (since discordant methylation-negative loss occurs).
    • Whether CpG methylation is sufficient and necessary for miR-34a tumor-suppressive phenotypes in vivo across diverse genetic backgrounds (e.g., p53 status, chromatin regulators). The paper suggests dominance over p53 transactivation in its models but does not quantify this across all contexts in the provided text.
    Author reviews (browsable on BGPT)


    Feedback:    

    Updated: March 27, 2026

     BGPT Paper Review


    Study Novelty

    70%

    The core novelty is linking miR-34a loss across multiple cancers to promoter CpG methylation with (i) methylation mapping, (ii) epigenetic reactivation, and (iii) functional consequences via CDK6 targetingβ€”an integration that was impactful for the field at the time, though miR-34/p53 and general miRNA-epigenetics were already established.


    Scientific Quality

    80%

    Mechanistically coherent evidence chain (methylation mapping β†’ pharmacologic reversion β†’ expression rescue β†’ phenotype + target validation). Main limitations include reliance on cultured cell lines for much prevalence inference, drug-level confounding (5Aza-2’dC/TSA off-target chromatin effects), and explicit discordant cases where expression loss is not methylation-positive. No attempt is described (in the provided text) to fully quantify effect sizes across diverse in vivo tumor settings.


    Study Generality

    60%

    The authors claim broad cancer applicability, but the prevalence evidence is largely from panels of established cell lines, with primary tissue validation limited (notably prostate and melanoma). Discordant inactivation mechanisms also constrain universality.


    Study Usefulness

    80%

    Provides a concrete, assayable molecular mechanism (miR-34a promoter methylation) and a functional target bridge (CDK6) that can inform mechanistic studies and biomarker assay design; however, the clinical predictive power and cross-cohort robustness are not established within this paper text.


    Study Reproducibility

    70%

    Methods are fairly specific (bisulfite sequencing, MSP primer sets/strategy positions, LNA ISH, Northern/RT-PCR, luciferase reporter with defined binding sites, pharmacologic schedules). Remaining reproducibility risk comes from primer-specific assay sensitivity and cell-line model dependence.


    Explanatory Depth

    80%

    The paper offers a reasonably deep mechanistic path: epigenetic silencing at the promoter level with demonstrated expression reversal and a functional target mechanism through CDK6 3’UTR site BS2, though it does not exhaustively map all miR-34a targets or all inactivation routes.


    🎁 Authors: Collect 301 Free Science Tokens (β‰ˆ $30.1 USD)

    Claim My Author Tokens

    Use for 75 days of free BGPT access (4 tokens = 1 day) or trade/sell (β‰ˆ $30.1 USD)

     Top Data Sources ExportMCP


     Analysis Wizard



    It extracts the paper’s methylation counts by cancer type and renders Plotly bar charts plus a concordance plot, enabling quick visual QC of the reported methylation–expression relationship.



     Hypothesis Graveyard


    A simplistic single-cause model (β€œmiR-34a is silenced in all cancers only by promoter CpG methylation”) is weakened by the paper’s own reported discordant cases (expression loss without substantial methylation in some samples/models).


    A simplistic transcription-only model (β€œp53 status alone determines miR-34a expression”) is weakened by the paper’s claim that methylation-driven silencing can dominate over p53 transactivation after DNA damage in their models.

     Science Art


    Paper Review: Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer Science Art

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT






     Trending